VTVT vTv Therapeutics Inc - Ordinary Shares - Class A

$VTVT If HPPD receives FDA approval and meets the relevant conditions, vTv could receive seven years of protection against FDA approval of the same drug for the same indication + development support + tax incentives + reduction of regulatory costs

$VTVT BUY support area REVERSAL MODE time to load the boat targets $44 $56 and $84 for long watch $AGEN and $RFL

$VTVT other major investors Samsara BioCapital, L.P 403,942 shares Invus Global Management, LLC 393,098 shares Trails Edge Capital Partners, LP 340,536 shares and Baker Bros. Advisors Lp are IN 148,314 shares

$VTVT "Completing enrollment for the CATT1 study is a significant milestone for vTv, and we're deeply grateful to the study participants whose commitment made this possible," said Paul Sekhri, Chairman, President and Chief Executive Officer of vTv Therapeutics. "Cadisegliatin has the potential to reduce the risk of hypoglycemia, which remains a significant unmet need for people living with T1D, and we look forward to completing the study and reporting topline results in mid 2027."

$VTVT Was 33.00 in the premarket with this orphan drug designation (I guess) what happen?

$VTVT nice update on cadisegliatin. Data in mid 2027. Hopefully this climbs up into data release.

$VTVT despite news so very little volume. At some point the very low volume will switch and the stock will be well below $30. Holding many short shares. If I could I would get many more short shares. Literally nothing bullish yet.

$VTVT too early to say it’s a reverse and one should buy. This company is really bad at communication and you could e soting many many more months before any data. Stock is barely higher on light volume. It would be Bette to buy under $30.

$VTVT Michael Tong said this morning that there will be a press release in coming weeks for completed enrollment of CAT1 Study. Add 6months for trial + time to look at data and that gets us to most likely Q2 2027 top line data readout.

$VTVT nice to see many big players in VTVT but still not bullish. They need data to make it go higher. No data is expected for close to a year.

$VTVT revised its bylaws, adopting a third amended and restated version that updates director nomination and voting procedures.

$VTVT may be worth an entry prior to cadisegliatin results for CATT1 trial. Point of concern is the study itself will not lead to FDA approval but could open the door to more funding for the P3 which can lead to approval...